Clinical Ink Competitors, Revenue, Alternatives and Pricing
Overview
Estimated Revenue & Financials
- Clinical Ink's estimated annual revenue is currently $29.9M per year.
- Clinical Ink received $Undisclosed in venture funding in May 2018.
- Clinical Ink's estimated revenue per employee is $201,000
- Clinical Ink's total funding is $21.7M.
Employee Data
- Clinical Ink has 149 Employees.
- Clinical Ink grew their employee count by 9% last year.
- Clinical Ink currently has 9 job openings.
Clinical Ink Competitors
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Online Review | Pricing |
|---|---|---|---|---|---|---|
| $5.6M | 185 | 7% | N/A | - | N/A | |
| $39.4M | 196 | 8% | N/A | - | N/A | |
| $2147.5M | 24959 | N/A | N/A | - | N/A | |
| $8.6M | 43 | 5% | N/A | - | N/A | |
| $49.2M | 245 | -1% | N/A | - | N/A | |
| $15.1M | 75 | 1% | N/A | - | N/A | |
| $12.3M | 61 | 30% | N/A | - | N/A | |
| $12.3M | 61 | 13% | N/A | - | N/A | |
| $20.1M | 100 | 12% | N/A | - | N/A | |
| $10.5M | 52 | -2% | N/A | - | N/A |
What Is Clinical Ink?
Clinical Ink is the leading provider of eSource solutions for the global clinical trials market. Founded in 2007, Clinical Ink® is transforming clinical development with innovative technologies that make clinical research easier for sites, sponsors and patients. Clinical Ink's SureSource® platform directly captures eSource data and documents and improves patient engagement while streamlining clinical development. Clinical Ink maintains offices in Winston-Salem, NC, and Philadelphia, PA. Find more at www.clinicalink.com. Our customer base includes pharmaceutical and medical device companies, academic institutions, and CROs. SureSource has been successfully used in a wide range of therapeutic areas including CNS, infectious diseases, dermatology, gastroenterology, and virology.
keywords:Healthcare,Pharmaceuticals149
Number of Employees
$29.9M
Revenue (est)
9
Current Jobs
9%
Employee Growth %
$21.7M
Total Funding
N/A
Valuation
N/A
Accelerator
B2B
Type
Clinical Ink News
Winston-Salem, N.C.; May 14, 2019 (PR Newswire) – Clinical Ink, a global clinical trial technology company that is transforming the clinical trial ...
Lupin's MEK inhibitor compound completed initial Phase-I clinical trial in the UK. Now, Boehringer will take over the clinical development of the ...
CDC, FDA, state and local health departments, and other clinical and public health partners are investigating a multistate outbreak of severe ...
Clinical Ink Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2013-10-17 | $4.3M | B | FCA Venture Partners | Article |
| 2015-03-19 | $Undisclosed | Undisclosed | MPM Capital | Article |
| 2018-05-15 | $Undisclosed | Undisclosed | RTI International | Article |
Clinical Ink Executive Hires
| Date | Name | Title | Reference |
|---|---|---|---|
| 2016-03-11 | Stephen Boccardo | Chief Commercial Officer | Article |
Clinical Ink Acquisitions
| Date | Company Name | Amount | Notes | Reference |
|---|---|---|---|---|
| 2015-03-19 | CentrosHealth | Article |